Praluent can be prescribed at general hospitals. As a result, practical competition for PCSK9 inhibitors began five years after domestic approval.

According to related industries, Sanofi-Aventis Korea's Praluent (Alirocumab) passed the Drug Committee of medical institutions such as Seoul National University Bundang Hospital, Gangnam Severance Hospital, Chonnam National University Hospital, and Pusan National University Hospital, including Asan Medical Center. Praluent was approved in Korea in January 2017, but it was not until June 2021 that insurance benefits were listed.

Amgen Korea's Repatha(Evolocumab) was approved in April 2017, and the willingness to register was stronger. Repatha